Research Article

Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients

Volume: 14 Number: 1 April 24, 2024
EN

Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients

Abstract

Objective: Deletions or loss of heterozygosity in chromosome 3p are very common in small-cell lung cancer (SCLC) and lung adenocarcinoma (ADC) cases. These are typically found in tumor cells but rarely observed in lymphocytes. This study aimed to evaluate the frequency of 3p deletions and/or abnormalities in the blood of lung cancer patients using conventional cytogenetics and fluorescence in situ hybridization (FISH), by targeting the fragile histidine triad diadenosine triphosphatase (FHIT) gene located at the commonly deleted region of 3p14.2, in lung cancers. Materials and Methods: The study examined 24 SCLC patients, 30 ADC patients, and 20 healthy controls. It used standard procedures to perform a 72-h lymphocyte culture, G-banding, and FISH. Results: All patient group cases showed multiple numerical and structural abnormalities, with numerical abnormalities being more prominent and involving all chromosomes. The following two 3p abnormalities were detected in one patient: del(3)(p22) and t(3;5)(p25;q31). FISH showed positive results regarding FHIT deletion in 9 (30%) ADC, and 7 (29%) SCLC patients. Conclusion: Regardless of the rarity of 3p abnormalities in lymphocytes, a high frequency of chromosomal aberrations may indicate genomic instability. Nevertheless, due to being a time-consuming and expertise-requiring technique, conventional cytogenetics is not recommended for lung cancer monitoring. However, the FISH results suggested that using FISH to examine FHIT gene status in lymphocytes could be a promising biomarker for lung cancer.

Keywords

References

  1. Schwendel A, Langreck H, Reichel M, Schröck E, Ried T, Dietel M, et al. Primary small-cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations. Int J Cancer 1997; 74(1): 86-93. google scholar
  2. Graziano SL, Cowan BY, Carney DN, Bryke CR, Mitter NS, Johnson BE, et al. Small cell lung cancer cell line derived from a primary tumor with a characteristic deletion of 3p. Cancer Res 1987; 47(8): 2148-55. google scholar
  3. Chang JG, Chen CC, Wu YY, Che TF, Huang YS, Yeh KT, et al. Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma. Oncotarget 2016; 7(45): 73664-80. google scholar
  4. Ashman JN, Brigham J, Cowen ME, Bahia H, Greenman J, Lind M, et al. Chromosomal alterations in small cell lung cancer revealed by multicolour fluorescence in situ hybridization. Int J Cancer 2002; 102(3): 230-6. google scholar
  5. Iijima H, Tomizawa Y, Dobashi K, Saito R, Nakajima T, Mori M. Allelic losses on chromosome 3p are accumulated in relation to morphological changes of lung adenocarcinoma. Br J Cancer 2004; 91(6): 1143-8. google scholar
  6. Petersen I, Langreck H, Wolf G, Schwendel A, Psille R, Vogt P, et al. Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p. Br J Cancer 1997; 75(1): 79-86. google scholar
  7. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996; 85(1): 17-26. google scholar
  8. Tarkan-Argüden Y, Hacihanefioglu S, Ongen G, Erk M, Cenani A. 3p abnormalities in peripheral lymphocytes in small cell lung cancer. Tumori 2009; 95(4): 535-7. google scholar

Details

Primary Language

English

Subjects

Genetics (Other)

Journal Section

Research Article

Publication Date

April 24, 2024

Submission Date

December 23, 2023

Acceptance Date

February 13, 2024

Published in Issue

Year 2024 Volume: 14 Number: 1

APA
Bakhshaliyeva, N., Çırakoğlu, A., Öngen, H. G., Tuncay, E. B., & Argüden, Y. (2024). Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients. Experimed, 14(1), 26-39. https://doi.org/10.26650/experimed.1408284
AMA
1.Bakhshaliyeva N, Çırakoğlu A, Öngen HG, Tuncay EB, Argüden Y. Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients. Experimed. 2024;14(1):26-39. doi:10.26650/experimed.1408284
Chicago
Bakhshaliyeva, Narmin, Ayşe Çırakoğlu, Hürrem Gül Öngen, Esin Bil Tuncay, and Yelda Argüden. 2024. “Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients”. Experimed 14 (1): 26-39. https://doi.org/10.26650/experimed.1408284.
EndNote
Bakhshaliyeva N, Çırakoğlu A, Öngen HG, Tuncay EB, Argüden Y (April 1, 2024) Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients. Experimed 14 1 26–39.
IEEE
[1]N. Bakhshaliyeva, A. Çırakoğlu, H. G. Öngen, E. B. Tuncay, and Y. Argüden, “Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients”, Experimed, vol. 14, no. 1, pp. 26–39, Apr. 2024, doi: 10.26650/experimed.1408284.
ISNAD
Bakhshaliyeva, Narmin - Çırakoğlu, Ayşe - Öngen, Hürrem Gül - Tuncay, Esin Bil - Argüden, Yelda. “Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients”. Experimed 14/1 (April 1, 2024): 26-39. https://doi.org/10.26650/experimed.1408284.
JAMA
1.Bakhshaliyeva N, Çırakoğlu A, Öngen HG, Tuncay EB, Argüden Y. Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients. Experimed. 2024;14:26–39.
MLA
Bakhshaliyeva, Narmin, et al. “Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients”. Experimed, vol. 14, no. 1, Apr. 2024, pp. 26-39, doi:10.26650/experimed.1408284.
Vancouver
1.Narmin Bakhshaliyeva, Ayşe Çırakoğlu, Hürrem Gül Öngen, Esin Bil Tuncay, Yelda Argüden. Cytogenetic and FISH Examination of 3p Abnormalities in Lung Cancer Patients. Experimed. 2024 Apr. 1;14(1):26-39. doi:10.26650/experimed.1408284